|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,079.00 CHF | +1.05% |
|
-0.52% | -2.13% |
| 02-10 | Goldman Sachs Downgrades Givaudan to Sell, Cuts PT | MT |
| 02-10 | Goldman Turns More Optimistic for Chemicals Sector - Recovery Gains Momentum | DP |
| Capitalization | 28.42B 36.98B 31.16B 27.13B 50.36B 3,349B 52.32B 331B 131B 1,617B 139B 136B 5,652B | P/E ratio 2026 * |
25.7x | P/E ratio 2027 * | 23.8x |
|---|---|---|---|---|---|
| Enterprise value | 31.75B 41.31B 34.81B 30.31B 56.26B 3,741B 58.46B 369B 147B 1,807B 155B 152B 6,315B | EV / Sales 2026 * |
4.17x | EV / Sales 2027 * | 3.94x |
| Free-Float |
82.78% | Yield 2026 * |
2.4% | Yield 2027 * | 2.46% |
Last Transcript: Givaudan SA
| 1 day | +1.05% | ||
| 1 week | -0.52% | ||
| Current month | +3.05% | ||
| 1 month | -4.38% | ||
| 3 months | -9.36% | ||
| 6 months | -7.26% | ||
| Current year | -2.13% |
| 1 week | 3,017 |  | 3,141 |
| 1 month | 2,895 | | 3,221 |
| Current year | 2,895 | | 3,237 |
| 1 year | 2,895 | | 4,236 |
| 3 years | 2,691 | | 4,690 |
| 5 years | 2,672 | | 4,871 |
| 10 years | 1,710 | | 4,871 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Andrier
CEO | Chief Executive Officer | 65 | 31/12/2004 |
Anne Tayac
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/2015 |
Louie D'Amico
PRN | Corporate Officer/Principal | 65 | 31/03/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Calvin Grieder
CHM | Chairman | 70 | 28/02/2017 |
Ingrid Deltenre
BRD | Director/Board Member | 66 | 31/12/2014 |
| Director/Board Member | 69 | 16/03/2016 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -.--% | 2.39% | 121 M€ | |
| -0.16% | 1.38% | 26 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.05% | -0.52% | -24.14% | +7.02% | 36.98B | |
| -0.51% | +3.04% | +13.01% | +82.48% | 84.74B | |
| -0.19% | +0.19% | -35.44% | -39.04% | 32.63B | |
| +0.20% | -0.43% | -5.44% | +40.74% | 23.91B | |
| +1.14% | -0.80% | +83.56% | -24.75% | 20.25B | |
| +4.67% | +1.82% | +104.84% | -39.02% | 19.6B | |
| 0.00% | +3.90% | -2.52% | -9.99% | 19.46B | |
| -0.06% | -1.14% | +21.96% | +112.26% | 15.64B | |
| -1.54% | +2.75% | +69.31% | -1.97% | 13.81B | |
| -0.05% | +4.85% | -23.78% | -20.27% | 12.61B | |
| Average | +0.48% | +1.66% | +20.14% | +10.75% | 27.96B | |
| Weighted average by Cap. | +0.31% | +1.68% | +12.95% | +24.89% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.6B 9.89B 8.34B 7.26B 13.48B 896B 14B 88.45B 35.11B 433B 37.11B 36.34B 1,513B | 7.95B 10.35B 8.72B 7.59B 14.09B 937B 14.64B 92.47B 36.71B 452B 38.8B 38B 1,581B |
| Net income | 1.12B 1.46B 1.23B 1.07B 1.98B 132B 2.06B 13.01B 5.16B 63.66B 5.46B 5.35B 222B | 1.2B 1.56B 1.32B 1.15B 2.13B 141B 2.21B 13.96B 5.54B 68.33B 5.86B 5.74B 239B |
| Net Debt | 3.33B 4.33B 3.65B 3.18B 5.9B 393B 6.13B 38.74B 15.38B 190B 16.25B 15.92B 663B | 2.92B 3.8B 3.2B 2.79B 5.17B 344B 5.37B 33.94B 13.47B 166B 14.24B 13.94B 580B |
Employees
17,580
Sector
Specialty Chemicals
Calendar
02-16
- Roadshow - BNP Exane
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/02/26 | 3,079.00 CHF | +1.05% | 24,056 |
| 12/02/26 | 3,047.00 CHF | -1.10% | 27,968 |
| 11/02/26 | 3,081.00 CHF | -1.09% | 23,497 |
| 10/02/26 | 3,115.00 CHF | +1.83% | 29,831 |
| 09/02/26 | 3,059.00 CHF | -1.16% | 14,373 |
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
3,079.00CHF
Average target price
3,621.14CHF
Spread / Average Target
+17.61%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GIVN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition